Original Publication Date: 7 July, 2016
Publication / Source: Nanomedicine
Authors: Nascimento TL, Hillaireau H, Vergnaud J, Fattal E
Much effort has been devoted over the past few decades to improve the treatment of cancer, and advances in nanotechnology and tumor biology have enabled the development of efficient nanocarriers to deliver therapeutic agents to the tumor tissue [1,2]. These nanocarriers have offered unique possibilities to overcome cellular barriers in order to improve the delivery of various drugs and drug candidates, including promising therapeutic biomacromolecules (i.e., nucleic acids, proteins) . In this context, one of the main adhesion/homing molecules involved in tumor progression and metastasis, CD44, has attracted much attention. Targeting these molecules is a promising approach in the treatment of cancer, since these receptors are expressed on many types of tumors and accumulate important functions such as supporting cell migration and transmitting survival signals through interactions with its numerous ligands [4–6].